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Abstract
Background: The aim of this study is to perform a cost-effectiveness comparison between
palpation-guided thyroid fine-needle aspiration biopsies (P-FNA) and ultrasound-guided thyroid
FNA biopsies (USG-FNA).
Methods: Each nodule was considered as a case. Diagnostic steps were history and physical
examination, TSH measurement, Tc99m thyroid scintigraphy for nodules with a low TSH level, initial
P-FNA versus initial USG-FNA, repeat USG-FNA for nodules with initial inadequate P-FNA or
USG-FNA, hemithyroidectomy for inadequate repeat USG-FNA. American Thyroid Association
thyroid nodule management guidelines were simulated in estimating the cost of P-FNA strategy.
American Association of Clinical Endocrinologists guidelines were simulated for USG-FNA
strategy. Total costs were estimated by adding the cost of each diagnostic step to reach a diagnosis
for 100 nodules. Strategy cost was found by dividing the total cost to 100. Incremental cost-
effectiveness ratio (ICER) was calculated by dividing the difference between strategy cost of USG-
FNA and P-FNA to the difference between accuracy of USG-FNA and P-FNA. A positive ICER
indicates more and a negative ICER indicates less expense to achieve one more additional accurate
diagnosis of thyroid cancer for USG-FNA.
Results: Seventy-eight P-FNAs and 190 USG-FNAs were performed between April 2003 and May
2008. There were no differences in age, gender, thyroid function, frequency of multinodular goiter,
nodule location and diameter (median nodule diameter: 18.4 mm in P-FNA and 17.0 mm in USG-
FNA) between groups. Cytology results in P-FNA versus USG-FNA groups were as follows: benign
49% versus 62% (p = 0.04), inadequate 42% versus 29% (p = 0.03), malignant 3% (p = 1.00) and
indeterminate 6% (p = 0.78) for both. Eleven nodules from P-FNA and 18 from USG-FNA group
underwent surgery. The accuracy of P-FNA was 0.64 and USG-FNA 0.72. Unit cost of P-FNA was
148 Euros and USG-FNA 226 Euros. The cost of P-FNA strategy was 534 Euros and USG-FNA
strategy 523 Euros. Strategy cost includes the expense of repeat USG-FNA for initial inadequate
FNAs and surgery for repeat inadequate USG-FNAs. ICER was -138 Euros.
Conclusion: Universal application of USG-FNA for all thyroid nodules is cost-effective and saves
138 Euros per additional accurate diagnosis of benign versus malignant thyroid nodular disease.
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Background
There are two thyroid nodule management guidelines
with global recognition: first is the management guide-
lines for patients with thyroid nodules and differentiated
thyroid cancer by American Thyroid Association (ATA)
Guidelines Taskforce and the second one is the American
Association of Clinical Endocrinologists (AACE) and
Associazione Medici Endocrinologi medical guidelines
for clinical practice for the diagnosis and management of
thyroid nodules. After identification of a thyroid nodule
that is more than 10–15 mm, ATA recommends measur-
ing serum TSH level. If TSH is low, a thyroid scan is next.
For a hot thyroid nodule, evaluation and treatment for
hyperthyroidism is recommended. If the nodule is not
hot, the algorithm points to diagnostic ultrasonography.
The flowchart directs again to diagnostic ultrasonography
for euthyroid and hypothyroid patients with thyroid nod-
ules. If a nodule is ultrasonographically confirmed, a cyto-
logical evaluation is next. ATA recommends ultrasound-
guided thyroid fine-needle aspiration biopsy (USG-FNA)
for nodules with more than 50% cystic component and
for nodules located in posterior parts of the thyroid gland.
Otherwise either palpation-guided (P-FNA) or USG-FNA
is next [1]. In contrast, as indicated in the abstract of their
guideline, AACE recommends universal application of
USG-FNA for all thyroid nodules ≥ 10 mm, except for sub-
jects with a low serum TSH level and a hot nodule, in
whom FNA is not indicated [2]. Except for minor changes
in the sequence of diagnostic steps, ATA and AACE thy-
roid nodule management guidelines differ only in the uti-
lization of ultrasound guidance. All previous studies show
that USG-FNA has higher sensitivity, specificity and accu-
racy than P-FNA [3-11]. A barrier for universal recommen-
dation of USG-FNA might be its higher initial cost [12].
The aim of this report is to compare cost-effectiveness
between palpation- and ultrasound-guided thyroid fine-
needle aspiration biopsies from a perspective of ATA ver-
sus AACE thyroid nodule management guidelines.
Methods
This is a secondary data analysis of a study registered to
ClinicalTrials.gov with Identifier NCT00571090. The aim
of the study was to identify ultrasonographic features that
predict malignant thyroid nodules. The primary data from
this study has not been published. Data relevant to cost-
effectiveness comparison are reported here. FNAs were
performed as an outpatient procedure in Gayrettepe and
Şis ¸li Florence Nightingale Hospitals, two private hospitals
affiliated with Istanbul Science University and authors'
private medical office in Şis ¸li, all located in Istanbul. Turk-
ish Cardiology Foundation owns and operates Istanbul
Science University and Group Florence Nightingale Hos-
pitals in Istanbul. These health care facilities are secondary
care centers for thyroid disorders, not tertiary care referral
centers.
The clinical information and cytology results of all consec-
utive patients who underwent FNA biopsy of thyroid nod-
ules in above-mentioned outpatient endocrinology clinics
were instantaneously recorded in a computerized data-
base on the day of the FNA biopsy. This study was not a
retrospective chart review. All patients were examined by
ASC, an endocrinologist who also performed all thyroid
FNA biopsies between April 2003 and May 2008. Thyroid
function tests and thyroid ultrasonography were routinely
obtained. Subjects were classified into euthyroid,
hypothyroid (TSH>4.20 μIU/ml) and hyperthyroid
(TSH<0.27 μIU/ml) categories according to the results of
thyroid function tests. The location, three dimensional
diameters, echo structure (solid, mixed or cystic), echo-
genecity (hypoechoic, isoechoic or hyperechoic) and
other ultrasonographic features of thyroid nodules were
recorded. A nodule was classified as cystic, if its area was
90–100% cystic. Thyroid scintigraphy with
Technetium99m was obtained for subjects with a low TSH
level. All subjects consented to FNA biopsy in accordance
with the hospital bylaws. Institutional Review Board
approval from Istanbul Science University Ethics Com-
mittee was asked and granted in July 2007 (Number
2007/006). As thyroid FNAs were performed in routine
clinical care without any investigational procedure, the
Ethics Committee did not ask for signed informed con-
sent for subjects enrolled prior to approval of the study.
Subjects admitted after July 2007 signed informed con-
sent for the study.
Each thyroid nodule was counted as a case in this report.
Three-hundred and thirty-nine FNAs were performed
between April 2003 and May 2008. Nineteen FNAs for
nonpalpable nodules and 16 FNAs for nodules <10 mm
were excluded. There were 19 nodules with a low TSH
level but without a thyroid scintigraphy and these were
also excluded. ATA designates cystic nodules as an indica-
tion for USG-FNA [1]. AACE recommends USG-FNA for
all nodules, including cystic ones [2]. As there was no dis-
agreement on the utility of ultrasound guidance for cystic
nodules between guidelines, 17 cystic nodules were
excluded from the analysis. There were 268 thyroid nod-
ules for comparison. One-hundred and ninety USG-FNAs
were performed to palpable thyroid nodules with a Son-
oSite 180 plus hand-carried ultrasound system and a L38/
10-5 MHz transducer between March 2004 and May
2008, starting with the acquisition of the ultrasound sys-
tem. Both the ultrasound system and the transducer were
manufactured by SonoSite Incorporation, located in
Bothell, WA, USA. A published standard technique was
used for USG-FNA [13]. Seventy-eight P-FNAs were per-
formed to palpable thyroid nodules with a previously
published technique [14] between April 2003 and Febru-
ary 2008, at times when the ultrasound system was not
available for FNA biopsy. Allocation to P-FNA and USG-BMC Endocrine Disorders 2009, 9:14 http://www.biomedcentral.com/1472-6823/9/14
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FNA groups was not random. The FNAs were done by pal-
pation-guidance until the ultrasonography system was
purchased. Then USG-FNA was routinely performed. P-
FNA was still performed after the acquisition of ultra-
sonography system, at times when the ultrasonography
machine was temporarily unavailable in the above-men-
tioned outpatient endocrinology clinics. On-site micro-
scopic adequacy was not determined. Local anesthesia
with 2% lidocaine was routinely administered for both P-
and USG-FNAs. All FNA biopsies were performed with
either 22 or 26 gauge needles. Twenty-two gauge needles
are long; 26 gauge needles are short. If the nodule is
located anteriorly or in the isthmus a 26 G needle, if pos-
teriorly a 22 G needle was used. Two needle aspirations
were carried out for each nodule. If no material was seen
on the slides to plain eye without using an optical instru-
ment, up to four aspirations were performed. Half of the
smears were air-dried and stained with May-Grünwald-
Giemsa and the other half were alcohol-fixed and stained
with Hematoxylene-Eosine or Papanicolaou. Cytological
diagnoses were categorized as malignant, benign, indeter-
minate and inadequate [1,14]. Six clusters of benign cells
in at least two slides constituted adequate material for
cytological diagnosis. Each cluster was composed of at
least 15 cells. The smears that do not meet these criteria
were assigned into inadequate category. Indeterminate
samples included a pattern of follicular or Hurthle cell
neoplasm or aspects of atypia suggestive, but not conclu-
sive of the presence of a malignant neoplasm [14].
Statistical methods
Continuous variables were presented as means ± standard
deviations and Student's t test was used for comparison.
As maximal nodule diameter had a positively skewed dis-
tribution, its logarithmic transformation was used in Stu-
dent's  t  test. Categorical variables were presented as
percentages and χ2 test was used for comparison. As the
expected frequencies of malignant results were less than
five in both groups, each cytology category in P-FNA and
USG-FNA groups was compared after collapsing the rest
of the categories. Fisher's exact test was employed when
the expected frequencies were less than five. Benign and
inadequate cytology results were categorized into negative
tests, as surgery is not recommended for these conditions.
Malignant and indeterminate FNA cytology results were
categorized into positive tests, as surgery is recommended
to patients with such results. Nodules with benign or
inadequate cytology and benign surgical histopathology
result were classified as true negatives. Nodules with
benign or inadequate cytology and malignant surgical his-
topathology result were classified as false negatives. Nod-
ules with malignant or indeterminate cytology and
malignant surgical histopathology result were classified as
true positives. Nodules with malignant or indeterminate
cytology and benign surgical histopathology result were
classified as false positives. The accuracy of the test was
calculated by dividing the sum of true positives and true
negatives to the sum of true positives, false positives, false
negatives and true negatives.
Cost of thyroid fine-needle aspiration strategies
Health care system of Republic of Turkey is dichotomized
to state (government) and private sector. According to
Turkish Ministry of Health, 10% of the population
receives services from private health care sector in Turkey
[15]. This study was performed in a private health care set-
ting. The minimum fee for medical and laboratory proce-
dures in private health care system is determined by the
City Chamber of Physicians, a non-governmental organi-
zation elected by physicians. Istanbul Chamber of Physi-
cians' minimum fees are used in this study and are shown
in table 1. Private health care sector charges the minimum
fee or usually up to two-fold of it. The minimum fee in
table 1 is valid for all private health care facilities in Istan-
bul. These were actual billed and collected fees obtained
from Gayrettepe Florence Nightingale Hospital Patients'
Accounts Office. Derived from patients' bills, subtotal
hemithyroidectomy fee includes all costs including one
night hospital stay but excludes the cost of harmonic scal-
pel, an expensive device that was used by some surgeons
in our hospital. ATA and AACE thyroid nodule manage-
ment guidelines were constructed using actual frequencies
from this study and actual costs from Table 1. The cost of
each diagnostic step was summed until a final cytological
or pathological diagnosis was made for one hundred nod-
ules. Malignant, benign and indeterminate cytological
results were final diagnoses. For inadequate smears, USG-
FNA was the next step whether or not initial FNA was pal-
pation- or ultrasound-guided. If two consecutive thyroid
FNAs were inadequate, a hemithyroidectomy was the
final procedure to reach a diagnosis [16]. Cost per nodule
was calculated by dividing the sum of costs for one hun-
dred nodules to 100. Incremental cost-effectiveness ratio
(ICER) was estimated to find the amount of more spend-
ing versus more saving to achieve one additional correct
Table 1: Cost of diagnostic steps recommended by thyroid 
nodule management guidelines
Diagnostic Step Cost
History and physical exam €39.03
Measurement of TSH €23.42
Thyroid ultrasonography €39.03
Tc99m thyroid scintigraphy €93.66
Palpation-guided FNA €148.30
Ultrasound-guided FNA €226.35
Subtotal hemithyroidectomy €1545.77
FNA: thyroid fine-needle aspiration biopsy. The exchange rate of 
European Central Bank on July 4th 2008 was used to convert costs in 
New Turkish Liras to Euros. 8% value addition tax is included. Costs 
are from Turkish private health care sector in Istanbul.BMC Endocrine Disorders 2009, 9:14 http://www.biomedcentral.com/1472-6823/9/14
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diagnosis of benign versus malignant thyroid nodule, if
one modality is used over the other. ICER [17] was calcu-
lated with the following formula:
cUSG-FNA is the cost of ultrasound-guided thyroid FNA
strategy according to AACE thyroid nodule management
guideline to achieve a diagnosis for one nodule, cP-FNA is
the cost of palpation-guided thyroid FNA strategy accord-
ing to ATA thyroid nodule management guideline to
achieve a diagnosis for one nodule, aUSG-FNA is the accu-
racy of ultrasound-guided thyroid FNA and aP-FNA is the
accuracy of palpation-guided FNA.
Results
In the palpation group, 36 patients had a solitary nodule
and 21 patients had two nodules, hence 78 FNAs were
performed by palpation. In the ultrasound-guided group,
102 patients had a solitary nodule, 38 patients had two
nodules and 4 patients had three nodules, hence 190
FNAs were performed with ultrasound-guidance. The fre-
quency of multinodular goiter was 37% in P-FNA and
29% in USG-FNA group (p = 0.29). The presence of multi-
nodular goiter was determined by ultrasonography on all
subjects. There were no differences in baseline characteris-
tics between P-FNA and USG-FNA groups (table 2). The
median maximal nodule diameter was 18.4 mm, the 25th
percentile 12.5 mm and 75th percentile 25.8 mm in the P-
FNA group. The median maximal nodule diameter was
17.0 mm, the 25th percentile 14.0 mm and 75th percentile
22.8 mm in the USG-FNA group. There were no differ-
ences in nodule diameter between groups (table 2). In the
USG-FNA group, significantly more subjects had benign
cytology results and significantly less number of subjects
had inadequate smears compared to P-FNA group. In the
P-FNA group, the echo structure of nodules with an inad-
equate result (n = 33) was 39.4% (n = 13) solid and 60.6%
(n = 20) mixed. The echogenecity of nodules with an inad-
equate result was 42.4% (n = 14) hypoechoic, 36.4% (n =
12) isoechoic, 12.1% (n = 4) hyperechoic, 9.1% (n = 3)
both hypoechoic and isoechoic in the P-FNA group. In the
USG-FNA group, the echo structure of nodules with an
inadequate result (n = 55) was 65.5% (n = 36) solid and
34.5% (n = 19) mixed. The echogenecity of nodules with
an inadequate result was 47.3% (n  = 26) hypoechoic,
41.8% (n = 23) isoechoic, 5.5% (n = 3) hyperechoic, 3.6%
(n = 2) both hypoechoic and isoechoic, 1.8% (n = 1) both
hypoechoic and hyperechoic in the USG-FNA group. Sig-
nificantly more nodules with an inadequate result had a
mixed echo structure in the P-FNA group (χ2 test, p =
0.02), but there were no differences in echogenecity
between P-FNA and USG-FNA groups (χ2 or Fisher's exact
test, p > 0.05). The frequency of malignant or indetermi-
nate diagnoses did not differ between groups. Eleven nod-
ules from P-FNA and 18 from USG-FNA group underwent
thyroid surgery (tables 3 and 4). In the palpation-guided
group, surgical histopathology showed two papillary thy-
roid carcinomas. One of the papillary carcinomas was
found to be malignant in prior cytology and was a true
positive. The other papillary carcinoma was reported as
benign in P-FNA cytology and was a false negative. There
were nine nodules that were benign in surgical histopa-
thology in the palpation group. In prior cytology, four of
them were benign and two of them were inadequate, so
there were six true negatives. Two of the histopathologi-
cally benign nodules were categorized as indeterminate
and one of them as malignant in prior cytology, so there
were three false positives. The nodule with the malignant
cytology and benign pathology was a benign adenoma-
tous nodule with lymphocytic thyroiditis, as well as the
first nodule with the indeterminate result. The other inde-
ICER
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Table 2: Comparison of baseline characteristics and cytology 
results between palpation-guided and ultrasound-guided thyroid 
fine-needle aspiration biopsies
P-FNA USG-FNA p-value
Nodule number (n) 78 190
Age (years)* 47 ± 15 47 ± 12 0.86
Men (%)† 14 (18%) 42 (22%) 0.45
Euthyroid (%)† 69 (89%) 158 (83%) 0.27
Hypothyroid (%)† 5 (6%) 20 (11%) 0.29
Hyperthyroid (%)‡ 4 (5%) 12 (6%) 1.00
Right lobe (%)† 39 (50%) 84 (44%) 0.48
Isthmus (%)† 12 (15%) 25 (13%) 0.48
Log (nodule diameter)*§ 1.26 ± 0.18 1.27 ± 0.19 0.58
Malignant (%)‡ 2 (3%) 6 (3%) 1.00
Benign (%)† 38 (49%) 118 (62%) 0.04
Indeterminate (%)‡ 5 (6%) 11 (6%) 0.78
Inadequate (%)† 33 (42%) 55 (29%) 0.03
Each case is a nodule, not a subject. P-FNA: palpation-guided thyroid 
fine-needle aspiration biopsy, USG-FNA: ultrasound-guided thyroid 
fine-needle aspiration biopsy *mean and standard deviation are given 
and Student's t test is used to compare groups †frequency and 
percentage are given and χ2 test is used to compare groups 
‡frequency and percentage are given and Fisher's exact test is used to 
compare groups. §logarithm of maximal nodule diameter expressed as 
log (mm).
Table 3: Cross-tabulation of cytology and surgical histopathology 
results in palpation-guided thyroid fine-needle aspiration 
biopsies
Disease positive Disease negative
Test positive 1 3
Test negative 1 6
Disease positive: malignant surgical histopathology, Disease negative: 
benign surgical histopathology, Test positive: malignant or 
indeterminate cytology result, test negative: benign or unsatisfactory 
cytology result.BMC Endocrine Disorders 2009, 9:14 http://www.biomedcentral.com/1472-6823/9/14
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terminate lesion was a micro- and macrofollicular colloid
nodule. Both indeterminate nodules had Hurthle cell
metaplasia in histopathology. Cross-tabulation of cytol-
ogy and pathology results in the P-FNA group was sum-
marized in table 3. The sensitivity of P-FNA was 0.50,
specificity 0.66 and accuracy 0.64. In the ultrasound-
guided group, surgical histopathology showed five papil-
lary, one follicular and four medullary thyroid carcino-
mas. Eight of these were found to be malignant in prior
cytology and were true positives. One medullary carci-
noma was reported as benign and the other as inadequate
in prior USG-FNA cytology, so there were two false nega-
tives. There was a high prevalence of medullary thyroid
cancer in the USG-FNA group. The medullary thyroid can-
cer patients were not relatives and there was no single
cluster of familial medullary thyroid carcinoma in the
USG-FNA group. There were eight nodules that were
benign in surgical histopathology in USG-FNA group. In
prior cytology, two of them were benign and three were
inadequate, so there were five true negatives. Three his-
topathologically benign nodules were categorized as inde-
terminate in prior cytology and were false positives. The
cytologically indeterminate lesions were adenomatous
nodules with lymphocytic thyroiditis in surgical histopa-
thology. Cross-tabulation of cytology and pathology
results in the USG-FNA group was summarized in table 4.
The sensitivity of USG-FNA was 0.80, specificity 0.63 and
accuracy 0.72.
Figure 1 shows that P-FNA strategy costs €534 per nodule,
if one follows ATA thyroid nodule management guide-
lines. As estimated in the previous paragraph, P-FNA cor-
rectly classifies 64% of palpable, non-cystic thyroid
nodules as benign versus malignant. Figure 2 shows that
USG-FNA strategy costs €523 per nodule, if one follows
AACE guidelines. As shown in the previous paragraph,
USG-FNA correctly classifies 72% of palpable, non-cystic
thyroid nodules as benign versus malignant. ICER is -
€138. The negative ICER means that utilization of USG-
FNA instead of P-FNA results in a saving of 138 Euros for
one additional correct diagnosis of thyroid malignancy.
Discussion
Although initial cost of USG-FNA is higher, this study
shows that universal USG-FNA for all thyroid nodules is
cost-effective compared to P-FNA strategy. Existing thy-
roid nodule management guidelines were simulated, an
approach not followed in previous studies. Other
researchers showed that thyroid FNA is cost-effective com-
pared to thyroid scintigraphy or to diagnostic ultrasonog-
raphy in detecting thyroid cancer [17,18]. This is the only
study that shows USG-FNA is cost-effective compared to
P-FNA. Previous studies showed that USG-FNA strategy is
expensive than P-FNA strategy [5,19], meaning that
although more accurate, USG-FNA is not cost-effective
compared to P-FNA. Cesur et al. reported that USG-FNA is
€13 expensive than P-FNA [5]. Khalid and coworkers
found that USG-FNA costs €184 more for one additional
correct diagnosis [19]. Existing data for cytology results
were compiled from the literature in that study. In Khalid
and coworkers' study, the inadequacy rate of P-FNA was
20%, the inadequacy rate of USG-FNA was 5%, the accu-
racy rate of P-FNA was 0.92 and the accuracy rate of USG-
FNA was 0.98 [19]. These were somewhat lower inade-
quate and higher accuracy rates than found in this study
and in studies given in table 5. When the inadequate
biopsy rate is low, like the studies of Danese et al. [3],
Izquierdo et al. [6] and Khalid et al. [19], USG-FNA is not
cost-effective over P-FNA and ICER, the extra cost to
achieve one more accurate diagnosis is over €250 (table
5). In other studies with higher inadequate rates [4,5],
ICER ranged between €58 and €90 (table 5). If the use of
harmonic scalpel becomes a standard in thyroid surgery
[20], the cost of thyroid surgery will increase. Khalid and
coworkers reported that when the cost of surgery
increases, USG-FNA becomes more cost-effective [19].
Manipulation of the data with alternatives
If the diagnostic step of hemithyroidectomy (n = 12 for P-
FNA and n = 8 for USG-FNA) is excluded from Figures 1 &
2, the average cost of P-FNA will be €349 and USG-FNA
€399 in this study. As the analyses reported here are sub-
ject to substantial changes depending on the variation of
costs and FNA outcomes, alternative data sources are
used. The first approach is to replace private health care
costs that are used in this study (table 1) with state hospi-
tals' costs in Turkey. Turkish Ministry of Health owns and
operates state hospitals and licenses and inspects private
hospitals. Turkish Ministry of Labor and Social Security
manages Turkish Social Security Institution which covers
80% of the population and is the main payer for health
care [21]. All state hospitals provide services to patients
insured by the Turkish Social Security Institution from the
prices that the Institution determines. Turkish Social Secu-
rity Institution's prices are obtained from the internet [21]
and Ankara University, Faculty of Medicine (Murat Faik
Erdogan, MD, murat.erdogan@temd.org.tr, e-mail com-
Table 4: Cross-tabulation of cytology and surgical histopathology 
results in ultrasound-guided thyroid fine-needle aspiration 
biopsies
Disease positive Disease negative
Test positive 8 3
Test negative 2 5
Disease positive: malignant surgical histopathology, Disease negative: 
benign surgical histopathology, Test positive: malignant or 
indeterminate cytology result, test negative: benign or unsatisfactory 
cytology result.BMC Endocrine Disorders 2009, 9:14 http://www.biomedcentral.com/1472-6823/9/14
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Cost calculation of palpation-guided thyroid fine-needle aspiration biopsy strategy Figure 1
Cost calculation of palpation-guided thyroid fine-needle aspiration biopsy strategy. Cost of diagnostics steps were 
summed until a final diagnosis was established for one hundred thyroid nodules for which initial palpation-guided thyroid fine-
needle aspiration biopsy was performed by simulating American Thyroid Association thyroid nodule management guideline. 
Strategy cost was calculated by dividing the total cost to 100. FNA: fine-needle aspiration biopsy.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History and physical examination 
(n=100) 
€39.03x100 
Normal/High TSH (n=96)  Low TSH (n=4) 
99Tc scan (n=4) 
Not hot 
(n=4) 
Hot 
(excluded) 
Diagnostic 
ultrasonography (n=100) 
>50% cystic 
(excluded) 
Not >50% 
cystic (n=100) 
No nodule 
(excluded) 
Initial palpation-guided FNA (n=100) 
Inadequate 
(n= 42) 
Malignant 
(n=3) 
Indeterminate 
(n=6) 
Benign 
(n=49) 
Repeat ultrasound-guided FNA 
(n=42) 
Adequate 
(n=30) 
Inadequate 
(n=12) 
Hemithyroidectomy (n=12) 
Sum of costs: 
€53408.58 
€23.42x100 
€39.03x100 
€148.30x100 
€93.66x4 
€226.35x42 
€1545.77x12 
Cost per nodule: 
€534 BMC Endocrine Disorders 2009, 9:14 http://www.biomedcentral.com/1472-6823/9/14
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Cost calculation of ultrasound-guided thyroid fine-needle aspiration biopsy strategy Figure 2
Cost calculation of ultrasound-guided thyroid fine-needle aspiration biopsy strategy. Cost of diagnostic steps were 
summed until a final diagnosis was established for one hundred thyroid nodules for which initial ultrasound-guided thyroid fine-
needle aspiration biopsy was performed by simulating American Association of Clinical Endocrinologists thyroid nodule man-
agement guideline. Strategy cost was calculated by dividing the total cost to 100. FNA: fine-needle aspiration biopsy, USG: 
ultrasonography.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History and physical 
examination (n=100) 
€39.03x100 
Normal TSH 
(n=83) 
99Tc scan (n=6) 
Cold 
(n=6) 
Hot 
(excluded) 
Initial ultrasound-guided FNA (n=100) 
Malignant 
(n=3) 
Indeterminate 
(n=6) 
Benign 
(n=62) 
Repeat ultrasound-guided FNA 
(n=29) 
Adequate (n=21)  Inadequate (n=8) 
Hemithyroidectomy (n=8) 
Cost per nodule
€523 
€23.42x100 
€39.03x100 
€226.35x100 
€93.66x6 
€226.35x29 
€1545.77x8 
High TSH 
(n=11) 
USG not 
suspicious 
(excluded) 
Low TSH 
(n=6) 
USG 
suspicious 
(n= 11) 
TSH & thyroid USG (n=100) 
Sum of costs: 
€52275.27 
Inadequate 
(n= 29) BMC Endocrine Disorders 2009, 9:14 http://www.biomedcentral.com/1472-6823/9/14
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munication, June 10, 2008). These prices were valid for all
state hospitals in Turkey in 2008. Following are Turkish
State Hospitals' fees: history and physical exam €8, TSH
measurement  €2.32, thyroid ultrasonography €7.49,
Tc99m thyroid scintigraphy €9.65, P-FNA €36.81, USG-
FNA €52.14, subtotal hemithyroidectomy €393.76. From
a perspective of Turkish Social Security Institution prices
and FNA outcomes of this study, P-FNA strategy costs
€124 and USG-FNA strategy costs €117 for one thyroid
nodule. ICER is -€88, again indicating savings with USG-
FNA. The next example is to input other authors' costs to
our thyroid FNA outcomes. From a mid-Atlantic academic
medical center in the USA, the cost of initial P-FNA was
reported as €162, USG-FNA as €263 and hemithyroidec-
tomy as €1733 [19]. These were hospital costs and were
not actual billed charges. When these costs are inputted
into the last five boxes of Figure 1 and 2, the cost of P-FNA
strategy is estimated as €480 and the cost of USG-FNA
strategy as €478. ICER is -€25, indicating savings with
USG-FNA strategy. The other approach is to use costs in
table 1 with inadequate and accuracy rates from the liter-
ature. A cost-effectiveness comparison is made by using
data from previous studies that report both the accuracy
rates and head-to-head comparison of P-FNA with USG-
FNA and is illustrated in table 5.
Limitation of the study
A cystic nodule was defined if the cystic component is
more than 90% of nodule area in this study. ATA recom-
mends USG-FNA if a nodule is more than 50% cystic [1].
Posterior location of the nodule, an indication for USG-
FNA was not recorded and could not be used in the con-
struction of ATA thyroid nodule management guidelines.
Another point to remember is that actual costs should be
approximately 30% lower in this study, because charges
for diagnostic steps, like physical examination or TSH are
for per patient, not for per nodule. There were four nod-
ules with medullary thyroid cancer from three patients in
the USG-FNA group. A genetic RET screening was
requested. It was refused by one subject, the other subject
was lost to follow-up and RET analysis is pending in the
third subject. The medullary thyroid cancer patients were
not from the same family. A single familial cluster of med-
ullary thyroid cancer was not present. The assignment to
P-FNA or USG-FNA groups was not affected by the pres-
ence of medullary thyroid cancer and there was no bias in
the study from that aspect. Our inadequacy rates are high
(42% for P-FNA and 29% for USG-FNA). Mehrotra and
coworkers reported an inadequacy rate of 47% for P-FNA
and 16% for USG-FNA [9]. Our inadequacy rates are not
greatly different from Mehrotra's rates. Cytology out-
comes of this study reflect everyday clinical practice. This
may be an advantage in a cost-effectiveness comparison,
because controlled studies may have different outcomes
than real-life situations.
Conclusion
From a perspective of ATA and AACE thyroid nodule man-
agement guidelines and with costs from Turkish health
care system, this study shows that USG-FNA is cost-effec-
tive. If universal USG-FNA is used instead of P-FNA, 138
Euros are saved for one additional accurate diagnosis of
benign versus malignant thyroid nodular disease.
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Table 5: Cost-effectiveness comparison between palpation- and ultrasound-guided thyroid fine-needle aspiration biopsies with costs 
from this study and outcomes from previous studies
Author Year n P-FNA 
Inadequate
P-FNA 
Strategy Cost*
P-FNA 
Accuracy
USG-FNA 
Inadequate
USG-FNA 
Strategy Cost*
USG-FNA 
Accuracy
ICER Reference
Danese 1998 9683 9% €2 7 00 . 7 34 % €337 0.76 +€2233 [3]
Hatada 1998 166 30% €3 9 50 . 4 81 7 % €413 0.68 +€90 [4]
Cesur 2006 285 32% €4 3 00 . 7 72 1 % €437 0.89 +€58 [5]
Izquierdo 
2006
376 11% €2 9 00 . 6 17 % €344 0.80 +€284 [6]
Can 2009 268 42% €5 3 40 . 6 42 9 % €523 0.72 -€138 This study
n: total number of nodules, P-FNA: palpation-guided thyroid fine-needle aspiration biopsy, Inadequate: inadequate rate, USG-FNA: ultrasound-
guided thyroid fine-needle aspiration biopsy, ICER: incremental cost-effectiveness ratio. ICER is calculated by dividing the difference between 
strategy cost of USG-FNA and strategy cost of P-FNA to the difference between accuracy of USG-FNA and P-FNA. A positive ICER value indicates 
more, a negative ICER value indicates less expense for USG-FNA strategy over P-FNA strategy *Strategy cost is derived from figure 1 or 2, table 1 
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